VTV Therapeutics

VTV Therapeutics is a clinical-stage biopharmaceutical company based in the United States. With approximately 11 employees, the company is focused on developing oral, small molecule drug candidates to treat type 1 diabetes and other chronic conditions. VTV's pipeline includes several drug candidates, including cadisegliatin, which is being investigated as a potential adjunctive therapy to insulin for type 1 diabetes.